Brainstorm Cell Therapeutics Inc. (BCLI) financial statements (2021 and earlier)

Company profile

Business Address 1325 AVENUE OF AMERICAS
NEW YORK, NY 10019
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments421781016
Cash and cash equivalents3811210
Short-term investments4065916
Receivables022101
Prepaid expense 011  
Other undisclosed current assets100000
Total current assets:43310101017
Noncurrent Assets
Other noncurrent assets831200
Total noncurrent assets:831200
TOTAL ASSETS:51711111117
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7166203
Accounts payable5155101
Accrued liabilities111102
Debt 1    
Other undisclosed current liabilities511300
Total current liabilities:11186613
Noncurrent Liabilities
Long-term debt and lease obligation51    
Operating lease, liability51
Other undisclosed noncurrent liabilities(5)     
Total noncurrent liabilities:51    
Total liabilities:16196613
Commitments and contingencies1     
Stockholders' equity
Stockholders' equity attributable to parent, including:35(12)561014
Common stock000000
Treasury stock, value(0)     
Additional paid in capital18510595868584
Accumulated deficit(149)(117)(94)(80)(75)(70)
Other undisclosed stockholders' equity attributable to parent  4   
Other undisclosed stockholders' equity(1)     
Total stockholders' equity:35(12)561014
TOTAL LIABILITIES AND EQUITY:51711111117

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(32)(23)(14)(5)(5)(9)
Operating loss:(32)(23)(14)(5)(5)(9)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(0)(0)0000
Net loss available to common stockholders, diluted:(32)(23)(14)(5)(5)(8)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(32)(23)(14)(5)(5)(8)
Comprehensive loss, net of tax, attributable to parent:(32)(23)(14)(5)(5)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: